论文部分内容阅读
慢性阻塞性肺疾病(COPD)是呼吸系统的常见病和多发病。现通过对丙酸氟替卡松/沙美特罗(ICS/LABA)在COPD治疗中的作用机制及研究进展进行综述,阐述沙美特罗/丙酸氟替卡松联合治疗可显著降低COPD患者呼吸道炎症、显著改善1秒最大呼气量(FEV1)、FEV1减退率、急性加重次数及生活质量,降低COPD患者所有原因病死率,而且耐受性良好,是COPD患者有效、安全的治疗方法。
Chronic obstructive pulmonary disease (COPD) is a common and frequently-occurring disease of the respiratory system. The mechanism and research progress of fluticasone propionate / salmeterol (ICS / LABA) in COPD are reviewed. It is concluded that salmeterol / fluticasone propionate combination therapy can significantly reduce respiratory inflammation in COPD patients and significantly improve 1 second Maximum expiratory volume (FEV1), FEV1 decline rate, the number of exacerbations and quality of life, reduce the mortality of all causes of COPD patients, and well tolerated, is an effective and safe COPD treatment.